Form 4: Enliven Therapeutics Director Ballal Exercises Options and Sells Shares Under 10b5-1 Plan

Director Rahul D. Ballal exercised stock options and sold shares of Enliven Therapeutics, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 20, 2024, Rahul D. Ballal, a director of Enliven Therapeutics, Inc., exercised stock options to acquire 13,278 shares of common stock at a price of $5.52 per share.
• Simultaneously, Ballal sold 13,278 shares of common stock at a weighted average price of $19.1642, with prices ranging from $19.005 to $19.405.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on October 19, 2023.
• Following these transactions, Ballal directly owns 22,341 shares of Enliven Therapeutics common stock and holds options for 19,571 shares.
• The reported share amounts reflect a 1-for-4 reverse stock split effected on February 23, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders can use this information to understand the trading activity of a key company insider.
• The transactions may have a minor impact on the stock price due to the volume of shares traded.

Key Dates